Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031
But if appetite falls and protein intake collapses, patients lose muscle along with fat
GLP-1 receptor agonists are a class of prescription medications that essentially function the same way as GLP-1 produced in the body
& Yiu, W
Real GLP-1 programs have labs, follow-ups, and providers who can spot side effects early and adjust treatment
US$ 26.66
US$ 25.18
US$ 25.76
